The introduction of intravitreal anti-vascular endothelial growth factor (VEGF) injections revolutionized clinical outcomes in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both potentially blinding retinal diseases. The gene discussed is VEGFA; the disease is diabetic macular edema.